Overview Dividends

(BHC) Bausch Health Companies - Ratings and Ratios

Exchange: NYSE • Country: Canada • Currency: USD • Type: Common Stock • ISIN: CA0717341071

Gastroenterology, Dermatology, Neurology, Ophthalmology, Aesthetics

BHC EPS (Earnings per Share)

EPS Growth (3Y CAGR): 4.54%
EPS Trend (3Y Correlation): 2.1%

BHC Revenue

Revenue Growth (3Y CAGR): 6.76%
Revenue Trend (3Y Correlation): 78.0%

Risk via 10d forecast
Volatility	61.3%
Value at Risk 5%th	82.0%

Reward
Sharpe Ratio	-0.50
Alpha	-42.24

Character
Hurst Exponent	0.652
Beta	0.433

Drawdowns 3y
Max DD	59.28%
Mean DD	26.48%

Description: BHC Bausch Health Companies November 11, 2025

Bausch Health Companies Inc. (NYSE:BHC) is a diversified specialty pharma and medical-device firm headquartered in Laval, Canada. It markets products across gastroenterology, hepatology, neurology, dermatology, generic and OTC medicines, aesthetic devices, and eye-care solutions. The business is organized into five segments: Salix (GI therapies), International (branded, generic, OTC, and aesthetic devices outside North America), Solta Medical (aesthetic devices), Diversified (neurology, dermatology, generics, dentistry), and Bausch + Lomb (vision-care, surgical and ophthalmic pharmaceuticals).

As of FY 2023, BHC generated roughly $2.5 billion in revenue, with an adjusted EBITDA margin near 15 % and net debt of about $5.3 billion, reflecting its capital-intensive acquisition strategy. Key economic drivers include an aging global population that fuels demand for chronic-disease treatments (especially GI and eye-care), continued growth in the OTC self-care market, and pricing pressure from generic competition. The company’s pipeline features several late-stage generic GI products and new ophthalmic formulations, which could improve margin expansion if successfully launched.

For a deeper quantitative assessment, you may find ValueRay’s detailed valuation model for BHC worth reviewing.

BHC Stock Overview

Market Cap in USD	2,444m
Sub-Industry	Pharmaceuticals
IPO / Inception	1994-03-29
Return 12m vs S&P 500	-40.58%
Analyst Rating	3.0 of 5

BHC Dividends

Currently no dividends paid

BHC Growth Ratios

CAGR	-3.61%
CAGR/Max DD Calmar Ratio	-0.06
CAGR/Mean DD Pain Ratio	-0.14
Current Volume	1919.8k
Average Volume	1726.6k

Piotroski VR‑10 (Strict, 0-10) 5.0

Net Income (362.0m TTM) > 0 and > 6% of Revenue (6% = 598.4m TTM)

FCFTA 0.86 (>2.0%) and ΔFCFTA 82.36pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue -54.59% (prev 8.93%; Δ -63.52pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 1.15 (>3.0%) and CFO 1.51b > Net Income 362.0m (YES >=105%, WARN >=100%)

NO Net Debt/EBITDA fails (EBITDA <= 0)

Current Ratio 0.19 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (NaN) change vs 12m ago NaN% (target <= -2.0% for YES)

Gross Margin 92.22% (prev 88.77%; Δ 3.45pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 71.62% (prev 35.66%; Δ 35.97pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio -0.17 (EBITDA TTM -221.2m / Interest Expense TTM 3.13b) >= 6 (WARN >= 3)

Altman Z'' -52.10

(A) -4.16 = (Total Current Assets 1.31b - Total Current Liabilities 6.75b) / Total Assets 1.31b

(B) -7.51 = Retained Earnings (Balance) -9.82b / Total Assets 1.31b

warn (B) unusual magnitude: -7.51 — check mapping/units

(D) -0.06 = Book Value of Equity -1.51b / Total Liabilities 26.84b

Total Rating: -52.10 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 47.93

1. Piotroski 5.0pt = 0.0

2. FCF Yield 4.93% = 2.47

3. FCF Margin 11.25% = 2.81

4. Debt/Equity -16.90 = -2.50

5. Debt/Ebitda 5.91 = -2.50

6. ROIC - WACC (= -4.64)% = -5.79

7. RoE -32.91% = -2.50

8. Rev. Trend 77.98% = 5.85

9. EPS Trend 2.07% = 0.10

What is the price of BHC shares?

As of November 11, 2025, the stock is trading at USD 6.40 with a total of 1,919,800 shares traded.
Over the past week, the price has changed by -6.02%, over one month by +5.79%, over three months by -3.90% and over the past year by -31.55%.

Is Bausch Health Companies a good stock to buy?

No, based on ValueRay´s Fundamental Analyses, Bausch Health Companies (NYSE:BHC) is currently (November 2025) a stock to sell. It has a ValueRay Fundamental Rating of 47.93 and therefor a negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of BHC is around 5.69 USD . This means that BHC is currently overvalued and has a potential downside of -11.09%.

Is BHC a buy, sell or hold?

Bausch Health Companies has received a consensus analysts rating of 3.00. Therefor, it is recommend to hold BHC.

Strong Buy: 0
Buy: 1
Hold: 5
Sell: 1
Strong Sell: 0

What are the forecasts/targets for the BHC price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	7.2	12%
Analysts Target Price	7.2	12%
ValueRay Target Price	6.1	-5.2%

BHC Fundamental Data Overview November 01, 2025

Market Cap USD = 2.44b (2.44b USD * 1.0 USD.USD)
P/E Trailing = 25.4231
P/E Forward = 1.5825
P/S = 0.248
P/B = 18.7773
P/EG = 0.6315
Beta = 0.433
Revenue TTM = 9.97b USD
EBIT TTM = -528.2m USD
EBITDA TTM = -221.2m USD
Long Term Debt = 18.94b USD (from longTermDebt, last fiscal year)
Short Term Debt = 2.67b USD (from shortTermDebt, last fiscal year)
Debt = 21.62b USD (from shortLongTermDebtTotal, last fiscal year)
Net Debt = -1.31b USD (from netDebt column, last quarter)
Enterprise Value = 22.75b USD (2.44b + Debt 21.62b - CCE 1.31b)
Interest Coverage Ratio = -0.17 (Ebit TTM -528.2m / Interest Expense TTM 3.13b)
FCF Yield = 4.93% (FCF TTM 1.12b / Enterprise Value 22.75b)
FCF Margin = 11.25% (FCF TTM 1.12b / Revenue TTM 9.97b)
Net Margin = 3.63% (Net Income TTM 362.0m / Revenue TTM 9.97b)
Gross Margin = 92.22% ((Revenue TTM 9.97b - Cost of Revenue TTM 776.0m) / Revenue TTM)
Gross Margin QoQ = 100.0% (prev 99.37%)
Tobins Q-Ratio = 17.39 (Enterprise Value 22.75b / Total Assets 1.31b)
Interest Expense / Debt = 9.26% (Interest Expense 2.00b / Debt 21.62b)
Taxrate = 64.54% (139.2m / 215.7m)
NOPAT = -187.3m (EBIT -528.2m * (1 - 64.54%)) [loss with tax shield]
Current Ratio = 0.19 (Total Current Assets 1.31b / Total Current Liabilities 6.75b)
Debt / Equity = -16.90 (negative equity) (Debt 21.62b / totalStockholderEquity, last fiscal year -1.28b)
Debt / EBITDA = 5.91 (negative EBITDA) (Net Debt -1.31b / EBITDA -221.2m)
Debt / FCF = -1.17 (Net Debt -1.31b / FCF TTM 1.12b)
Total Stockholder Equity = -1.10b (last 4 quarters mean from totalStockholderEquity)
RoA = 27.68% (Net Income 362.0m / Total Assets 1.31b)
RoE = -32.91% (negative equity) (Net Income TTM 362.0m / Total Stockholder Equity -1.10b)
RoCE = -2.96% (EBIT -528.2m / Capital Employed (Equity -1.10b + L.T.Debt 18.94b))
RoIC = -0.91% (negative operating profit) (NOPAT -187.3m / Invested Capital 20.55b)
WACC = 3.72% (E(2.44b)/V(24.06b) * Re(7.61%) + D(21.62b)/V(24.06b) * Rd(9.26%) * (1-Tc(0.65)))
Discount Rate = 7.61% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: 100.0 | Cagr: 1.07%
[DCF Debug] Terminal Value 70.46% ; FCFE base≈1.04b ; Y1≈679.6m ; Y5≈310.8m
Fair Price DCF = 16.52 (DCF Value 6.11b / Shares Outstanding 369.8m; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: 2.07 | EPS CAGR: 4.54% | SUE: 0.38 | # QB: 0
Revenue Correlation: 77.98 | Revenue CAGR: 6.76% | SUE: -0.01 | # QB: 0

Additional Sources for BHC Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle